137 related articles for article (PubMed ID: 11213813)
1. Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Falkenberg M; Holmdahl L; Tjärnström J; Risberg B
Eur J Surg; 2001 Jan; 167(1):10-4. PubMed ID: 11213813
[TBL] [Abstract][Full Text] [Related]
2. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms.
Lindholt JS; Jørgensen B; Shi GP; Henneberg EW
Eur J Vasc Endovasc Surg; 2003 Jun; 25(6):546-51. PubMed ID: 12787697
[TBL] [Abstract][Full Text] [Related]
3. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.
Coolman M; de Groot CJ; Steegers EA; Geurts-Moespot A; Thomas CM; Steegers-Theunissen RP; Sweep FC
Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):22-8. PubMed ID: 16584829
[TBL] [Abstract][Full Text] [Related]
4. Changes in pericardial morphology and fibrinolytic activity during cardiopulmonary bypass.
Nkere UU; Whawell SA; Thompson EM; Thompson JN; Taylor KM
J Thorac Cardiovasc Surg; 1993 Aug; 106(2):339-45. PubMed ID: 8341074
[TBL] [Abstract][Full Text] [Related]
5. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease.
Reilly JM; Sicard GA; Lucore CL
J Vasc Surg; 1994 May; 19(5):865-72. PubMed ID: 8170041
[TBL] [Abstract][Full Text] [Related]
6. Enhanced PAI-1 levels from early second trimester and during labour and plasminogen activators in normal pregnancy.
Koh SC; Anandakumar C; Biswas A; Fong YF
Thromb Haemost; 2002 Jan; 87(1):175-6. PubMed ID: 11858184
[No Abstract] [Full Text] [Related]
7. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Koelbl H; Kirchheimer JC; Tatra G; Christ G; Binder BR
Obstet Gynecol; 1988 Aug; 72(2):252-6. PubMed ID: 3134631
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M
Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase expressions in arteriosclerotic aneurysmal disease.
Saito S; Zempo N; Yamashita A; Takenaka H; Fujioka K; Esato K
Vasc Endovascular Surg; 2002; 36(1):1-7. PubMed ID: 12704518
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
11. Basal release of urokinase plasminogen activator, plasminogen activator inhibitor-1, and soluble plasminogen activator receptor from separated and cultured endometriotic and endometrial stromal and epithelial cells.
Bruse C; Guan Y; Carlberg M; Carlström K; Bergqvist A
Fertil Steril; 2005 Apr; 83 Suppl 1():1155-60. PubMed ID: 15831288
[TBL] [Abstract][Full Text] [Related]
12. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
14. Systemic haemostasis after intermittent pneumatic compression. Clues for the investigation of DVT prophylaxis and travellers thrombosis.
Giddings JC; Morris RJ; Ralis HM; Jennings GM; Davies DA; Woodcock JP
Clin Lab Haematol; 2004 Aug; 26(4):269-73. PubMed ID: 15279664
[TBL] [Abstract][Full Text] [Related]
15. Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta.
Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC
J Vasc Surg; 1997 Jan; 25(1):157-64. PubMed ID: 9013920
[TBL] [Abstract][Full Text] [Related]
16. Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells.
Guan YM; Carlberg M; Bruse C; Carlström K; Bergqvist A
Acta Obstet Gynecol Scand; 2002 May; 81(5):389-97. PubMed ID: 12027810
[TBL] [Abstract][Full Text] [Related]
17. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
18. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
19. The operative peritoneal fibrinolytic response to abdominal operation.
Scott-Coombes DM; Whawell SA; Thompson JN
Eur J Surg; 1995 Jun; 161(6):395-9. PubMed ID: 7548374
[TBL] [Abstract][Full Text] [Related]
20. Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms.
Houard X; Rouzet F; Touat Z; Philippe M; Dominguez M; Fontaine V; Sarda-Mantel L; Meulemans A; Le Guludec D; Meilhac O; Michel JB
J Pathol; 2007 May; 212(1):20-8. PubMed ID: 17352452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
